Defunct Company
Total Trials
2
As Lead Sponsor
0
As Collaborator
Total Enrollment
88
NCT02331433
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
Phase: Phase 1
Role: Collaborator
Start: Dec 31, 2014
Completion: Dec 31, 2015
NCT02724917
Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
Phase: Phase 1/2
Start: Apr 30, 2016
Completion: Dec 31, 2016